Background: Cognitive impairment is a common consequence of stroke and is associated with poor functional outcome and higher risk of recurrent cerebrovascular stroke. Serum Malondialdehyde (MDA) is used as a biomarker to measure the oxidative stress. The association of serum MDA levels in acute ischemic stroke and post-stroke cognitive impairment (PSCI) is infrequently been studied.
Objective: This study aimed to identify the relationship between serum MDA levels in the first week after acute ischemic stroke, and PSCI after three months.
Methods: Thirty-seven patients 17 males (45.9%) and 20 females (54.1%) with acute ischemic stroke recruited from Neurology critical care units, Zagazig University hospitals were prospectively enrolled in follow-up cohort study. Serum MDA was measured within 24 h after admission. Cognitive outcome after three months was assessed by Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA).
Results: 43.2% of patients had no cognitive impairment while 35.1%had mild and 21.6% had severe cognitive impairment according to MMSE and 59.5%had unfavorable MoCA outcomes. There was a significant negative correlation between serum MDA and MMSE and MoCA.
Conclusion: Increasing MDA serum level had a significant effect on development of PSCI.